Document ID: chunk:federal_register_of_legislation:F2025C00199:schedule:3:p2
Version: federal_register_of_legislation:F2025C00199
Segment Type: schedule
Provision Reference: sch 3 (pt 2/9)
Character Range: 70165–73021

laboratory rabbit, a genetically modified laboratory rat or a genetically modified Caenorhabditis elegans, if:
 (i) the genetic modification confers an advantage on the animal; and
 (ii) the animal is not capable of secreting or producing an infectious agent as a result of the genetic modification;
 (b) a dealing involving a genetically modified plant;
 (c) a dealing involving a host/vector system not mentioned in paragraph 1.1(c) or Part 2 of Schedule 2, if neither host nor vector has been implicated in, or has a history of causing, disease in otherwise healthy:
 (i) human beings; or
 (ii) animals; or
 (iii) plants; or
 (iv) fungi;
 (d) a dealing involving a host/vector system not mentioned in Part 2 of Schedule 2, if:
 (i) the host or vector has been implicated in, or has a history of causing, disease in otherwise healthy:
 (A) human beings; or
 (B) animals; or
 (C) plants; or
 (D) fungi; and
 (ii) the genetic modification is characterised; and
 (iii) the characterisation of the genetic modification shows that it is unlikely to increase the capacity of the host or vector to cause harm;
                   Example: A genetic modification would not comply with subparagraph (iii) if, in relation to the capacity of the host or vector to cause harm, it:
                   (a) provides an advantage; or
                   (b) adds a potential host species or mode of transmission; or
                   (c) increases its virulence, pathogenicity or transmissibility.
 (e) a dealing involving a host/vector system mentioned in Part 2 of Schedule 2, if the donor nucleic acid:
 (i) is characterised, and the characterisation shows that it may increase the capacity of the host or vector to cause harm; or
 (ii) is uncharacterised nucleic acid from an organism that has been implicated in, or has a history of causing, disease in otherwise healthy:
 (A) human beings; or
 (B) animals; or
 (C) plants; or
 (D) fungi;
 (f) a dealing involving a host/vector system mentioned in Part 2 of Schedule 2 and producing more than 25 litres of GMO culture in each vessel containing the resultant culture, if:
 (i) the dealing is undertaken in a facility that is certified by the Regulator as a large scale facility; and
 (ii) the donor nucleic acid satisfies the conditions set out in subitem 4(2) of Part 1 of Schedule 2;
 (g) a dealing involving complementation of knocked‑out genes, if the complementation is unlikely to increase the capacity of the GMO to cause harm compared to the capacity of the parent organism before the genes were knocked out;
                Example: A dealing would not comply with paragraph (g) if it involved complementation that, in relation to the parent organism:
                 (a) provides an advantage; or
                 (b) adds a potential host species or mode of transmission; or
                 (c) increases